{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:33:17Z","timestamp":1793665997205,"version":"4.5.1"},"reference-count":22,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p><jats:boxed-text position=\"float\" orientation=\"portrait\"><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.goo.gl\/4cka77\">Click here to listen to the Podcast<\/jats:ext-link><\/jats:p><\/jats:boxed-text><\/jats:p><jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>To compare the efficacy of combined intravitreal injection of bevacizumab and a Rho-kinase inhibitor, fasudil (intravitreal bevacizumab (IVB)\/intravitreal fasudil (IVF)), with IVB alone for centre-involving diabetic macular oedema (DME).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective randomised clinical trial, 44 eyes with centre-involving DME were randomised into two groups. The combined group received three consecutive injections of IVB (1.25\u2009mg) and IVF (50\u2009\u00b5M\/L) monthly, while the monotherapy group received only one IVB (1.25\u2009mg) injection per month for 3\u2009months. Changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were compared between the two groups at months 3 and 6. The primary outcome measure was the mean change in BCVA at month 6.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean BCVA was significantly improved in both groups at month 3 (P&lt;0.001), but it persisted up to month 6 only in the IVB\/IVF group. Improvement of BCVA was greater in the IVB\/IVF group at both time points (P=0.008, P&lt;0.001). In the IVB\/IVF and IVB groups, 54.5% versus 10% of the eyes gained\u226515 ETDRS letters at month 6 (P=0.026). Between months 3 and 6, mean BCVA significantly decreased by 5\u00b17 ETDRS letters in the IVB group (P=0.002), while no significant deterioration was observed in the IVB\/IVF group. Corresponding with the BCVA changes, CMT was significantly reduced in both groups at month 3 (p=0.006, p&lt;0.001) but this reduction sustained only in the IVB\/IVF group up to month 6 (p&lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adjunctive intravitreal injection of a Rho-kinase inhibitor may enhance and prolong the therapeutic effects of anti-vascular endothelial growth factor drugs for centre- involving DME.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2018-312244","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T16:18:20Z","timestamp":1535386700000},"page":"922-927","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":48,"title":["Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial"],"prefix":"10.1136","volume":"103","clinical-trial-number":[{"clinical-trial-number":"nct01823081","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hamid","family":"Ahmadieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Nourinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hafezi-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Sabbaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souska","family":"Zandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Yaseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Tofighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Akbarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,8,27]]},"reference":[{"key":"2020050713041981000_103.7.922.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-012-0283-6"},{"key":"2020050713041981000_103.7.922.2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5318\/wjo.v5.i2.55","article-title":"State of the art management of diabetic macular edema","volume":"5","author":"Nourinia","year":"2015","journal-title":"World J Ophthalmol"},{"key":"2020050713041981000_103.7.922.3","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-1476fje"},{"key":"2020050713041981000_103.7.922.4","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.135640"},{"key":"2020050713041981000_103.7.922.5","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.145.6.1293"},{"key":"2020050713041981000_103.7.922.6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10757"},{"key":"2020050713041981000_103.7.922.7","doi-asserted-by":"publisher","DOI":"10.2337\/db08-0762"},{"key":"2020050713041981000_103.7.922.8","doi-asserted-by":"crossref","unstructured":"Nourinia R , Nakao S , Zandi S , et al . ROCK inhibitors for the treatment of ocular diseases. Br J Ophthalmol 2017:bjophthalmol-2017-310378.doi:10.1136\/bjophthalmol-2017-310378","DOI":"10.1136\/bjophthalmol-2017-310378"},{"key":"2020050713041981000_103.7.922.9","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamaophthalmol.2013.143","article-title":"Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment","volume":"131","author":"Ahmadieh","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2020050713041981000_103.7.922.10","first-page":"337","article-title":"Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study","volume":"8","author":"Nourinia","year":"2013","journal-title":"J Ophthalmic Vis Res"},{"key":"2020050713041981000_103.7.922.11","doi-asserted-by":"publisher","DOI":"10.1080\/08820530490519934"},{"key":"2020050713041981000_103.7.922.12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000360909","article-title":"Effect of macular ischemia on intravitreal ranibizumab treatment for diabetic macular edema","volume":"232","author":"Douvali","year":"2014","journal-title":"Ophthalmologica"},{"key":"2020050713041981000_103.7.922.13","doi-asserted-by":"crossref","unstructured":"Zhang X , Zeng H , Bao S , et al . Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci 2014;4:27.doi:10.1186\/2045-3701-4-27","DOI":"10.1186\/2045-3701-4-27"},{"key":"2020050713041981000_103.7.922.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.09.037"},{"key":"2020050713041981000_103.7.922.15","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-215715"},{"key":"2020050713041981000_103.7.922.16","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.135.2.497"},{"key":"2020050713041981000_103.7.922.17","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200112126"},{"key":"2020050713041981000_103.7.922.18","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.24.8467-8477.2002"},{"key":"2020050713041981000_103.7.922.19","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-11103"},{"key":"2020050713041981000_103.7.922.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.033"},{"key":"2020050713041981000_103.7.922.21","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.128"},{"key":"2020050713041981000_103.7.922.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804054105"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2018-312244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:57:50Z","timestamp":1601110670000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-312244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,27]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,6,21]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bjophthalmol-2018-312244"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312244","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,27]]}}}